Neuphoria Therapeutics Inc. (NEUP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
100 Summit Dr
Burlington, MA 01803
United States of America (the)
Phone
N/A
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
December 16, 2021
| Name | Title | Pay | Year Born |
| Spyridon Papapetropoulos | Interim CEO, President & Executive Director | 827,683 | 1973 |
| Adrian Hinton | Financial Controller | 211,580 | 1952 |
| Elizabeth Doolin | Senior Vice President of Clinical Development | 218,799 | 1965 |
| Timothy Cunningham | Chief Financial Officer | 254,363 | 1962 |
| Rajeev Chandra | Company Secretary | 0 | N/A |
| Julie Kerner | Senior Vice President of Business Operations | 0 | N/A |
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.